Tracking the implementation of NCCLS M100-S12 expanded-spectrum cephalosporin MIC breakpoints for nonmeningeal isolates of Streptococcus pneumoniae by clinical laboratories in the United States during 2002 and 2003 by Master, Ronald N et al.
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
Annals of Clinical Microbiology and 
Antimicrobials
Open Access Research
Tracking the implementation of NCCLS M100-S12 
expanded-spectrum cephalosporin MIC breakpoints for 
nonmeningeal isolates of Streptococcus pneumoniae by clinical 
laboratories in the United States during 2002 and 2003
Ronald N Master, Deborah C Draghi, Mark E Jones, Clyde Thornsberry, 
Daniel F Sahm and James A Karlowsky*
Address: Focus Technologies, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171-4603. USA
Email: Ronald N Master - rmaster@focustechnologies.com; Deborah C Draghi - ddraghi@focustechnologies.com; 
Mark E Jones - mjones@focustechnologies.com; Clyde Thornsberry - cthornsberry@focustechnologies.com; 
Daniel F Sahm - dsahm@focustechnologies.com; James A Karlowsky* - jkarlowsky@focustechnologies.com
* Corresponding author    
Abstract
Background:  The Performance Standards for Antimicrobial Susceptibility Testing, Twelfth
Informational Supplement, M100-S12, published by the National Committee for Clinical Laboratory
Standards (NCCLS) in January 2002 introduced distinct minimum inhibitory concentration (MIC)
interpretative breakpoints for ceftriaxone, cefotaxime, and cefepime for nonmeningeal isolates of
Streptococcus pneumoniae. Previously, a single set of interpretative breakpoints was used for both
meningeal and nonmeningeal isolates.
Methods: To estimate the rate of adoption of the M100-S12 interpretive breakpoints by clinical
laboratories, antimicrobial susceptibility test results for ceftriaxone and cefotaxime from
nonmeningeal S. pneumoniae isolates were studied using data collected from January 2002 to June
2003 by The Surveillance Network® Database – USA (TSN®), an electronic surveillance database.
Results: Of the 262 laboratories that provided data that could be evaluated, 67.6% had adopted
the M100-S12 breakpoints one and one-half years after they were published.
Conclusions: The NCCLS M100-S12 recommendation to interpret MICs to expanded-spectrum
cephalosporins using two distinct sets of breakpoints for meningeal and nonmeningeal isolates of
S. pneumoniae was steadily implemented by clinical microbiology laboratories in the United States
following their initial publication in January 2002. The use of these new breakpoints more
accurately reflects the clinical activities of expanded-spectrum cephalosporins than did the single
set of interpretative breakpoints previously used for both meningeal and nonmeningeal isolates.
Background
Ceftriaxone, cefotaxime, and cefepime minimum inhibi-
tory concentration (MIC) interpretive breakpoints for
meningeal and nonmeningeal isolates of Streptococcus
pneumoniae  were published in January 2002 by the
National Committee for Clinical Laboratory Standards
(NCCLS) in their M100-S12 document [1]. Previously, a
single set of breakpoints was used to interpret ceftriaxone,
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cefotaxime, and cefepime MICs for both meningeal and
nonmeningeal  S. pneumoniae isolates [2]. These break-
points were initially published in 1996 and remained
unchanged through December 2001. For ceftriaxone and
cefotaxime, the M100-S12 guidelines advise laboratories
to report both meningeal and nonmeningeal interpreta-
tions for pneumococcal isolates recovered from body sites
other than cerebrospinal fluid. Ceftriaxone and cefotax-
ime MICs for isolates from cerebrospinal fluid should be
reported with meningitis interpretative criteria only. Since
cefepime does not have an approved indication for men-
ingitis in the U.S., the recommendation is to report only
the nonmeningitis interpretations for this agent [1]. A pre-
vious study based on historical data showed the M100-
S12 ceftriaxone and cefotaxime interpretive breakpoints
for nonmeningeal isolates decreased the number of S.
pneumoniae isolates interpreted as intermediate by 10%
and as resistant by 3 to 4% [3]. A second study, by Jones
and colleagues, showed a 9.1 to 13.0% increase in suscep-
tibility to cefotaxime, ceftriaxone, and cefepime using the
M100-S12 nonmeningeal interpretive criteria [4]. The cur-
rent study was conducted to determine the rate at which a
set of clinical laboratories in the United States adopted the
M100-S12 interpretive breakpoint changes from January
2002 to June 2003.
Methods
The Surveillance Network Database – USA (TSN), an elec-
tronic database that collects MICs, MIC categorical inter-
pretation data, and other microbiology laboratory data
from 326 U.S. clinical microbiology laboratories, was
used as the source of antimicrobial susceptibility test data
[5]. Nonmeningeal isolates of S. pneumoniae were limited
to those isolated from blood and respiratory tract sources.
Respiratory tract isolates included those from both the
upper and lower respiratory tracts. Ceftriaxone and cefo-
taxime MICs and corresponding susceptible, intermedi-
ate, and resistant interpretations were cross-referenced to
determine if laboratories used the M100-S11 [2] or the
M100-S12 [1] nonmeningeal S. pneumoniae MIC interpre-
tive breakpoints to interpret the MICs they generated.
Cefepime was not included in this analysis as only 16 lab-
oratories reported results (n = 572) for this agent. Sixty-
four TSN laboratories did not report assessable data for
ceftriaxone or cefotaxime during the time period of the
study. Laboratories were not assessable if they did not test
cefotaxime or ceftriaxone against S. pneumoniae or did not
report MIC values of 1 or 2 µg/ml. The breakpoint stand-
ard used could only be inferred when MIC values of 1 or
2 µg/ml were obtained.
In addition, a questionnaire was sent to laboratories in
September 2002, inquiring if the M100-S12 nonmenin-
geal breakpoints were in use at their laboratory. Laborato-
ries that had not adopted the new breakpoints were asked
why the changes had not been implemented, if they
would be implemented, and when they would be imple-
mented. Only laboratories that had assessable MIC data
and returned a completed questionnaire were included in
the analysis of the questionnaire data set.
To determine the effect of not adopting the new interpre-
tations, MICs from 12,827 nonmeningeal isolates of S.
pneumoniae  tested against ceftriaxone and cefotaxime
from January 2002 to June 2003 were evaluated and sus-
ceptible, intermediate, and resistant interpretation rates
for ceftriaxone and cefotaxime were calculated using both
the M100-S11 and M100-S12 breakpoints.
Results
Two hundred sixty-two TSN laboratories were included in
the overall analysis. One hundred and seventy-four labo-
ratories were included in the analysis for ceftriaxone and
200 laboratories were included for cefotaxime. Table 1
compares the number of laboratories with interpretable
data that were using the M100-S11 or M100-S12 criteria
by quarter from January 2002 to June 2003. Cross-refer-
encing quantitative (MICs) and qualitative (susceptible,
intermediate, resistant) data showed that at the end of
January 2002, 13.1% (11/84) of laboratories reporting
ceftriaxone results and 17.4% (22/126) of laboratories
reporting cefotaxime results used the new M100-S12
breakpoints (data not shown). The proportion of labora-
tories using the M100-S12 breakpoints for ceftriaxone and
cefotaxime increased an average of 3% per month from
January 2002 to June 2003. By September 2002, 36% (90/
250) of laboratories reporting results for expanded-spec-
trum cephalosporins used the M100-S12 breakpoints.
One hundred seventy-three of 262 laboratories (66.0%)
responded to the questionnaire sent in September 2002.
Among the laboratories responding to the questionnaire,
53.2% (92/173) stated they were using the M100-S12
breakpoints and 46.8% (81/173) of laboratories had not
yet adopted the new breakpoints. Of the respondents that
were not using the M100-S12 breakpoints, nearly one-half
attributed this to difficulty in modifying their laboratory
information system (LIS) or to not having information
systems staff available to make the necessary changes.
Thirty-six percent (29/81) of the responding laboratories
that stated they were not currently using the new break-
points reported that they planned to adopt the new break-
points by the end of 2002.
By the end of 2002, 42.6% (109/256) of laboratories with
data that could be evaluated had adopted the M100-S12
nonmeningeal  S. pneumoniae cefotaxime or ceftriaxone
interpretive breakpoints and 57.4% (147/256) of labora-
tories continued to use the M100-S11 breakpoints. The
laboratories that adopted the M100-S12 breakpointsAnnals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/1
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included 44.6% (74/166) of laboratories reporting ceftri-
axone and 28.1% (55/196) of laboratories reporting cefo-
taxime. By June 2003, 67.6% (177/262) of laboratories
with data that could be evaluated had adopted the M100-
S12 nonmeningeal S. pneumoniae cefotaxime or ceftriax-
one interpretive breakpoints and 32.4% (85/262) of lab-
oratories continued to use the M100-S11 breakpoints. The
laboratories that adopted the M100-S12 breakpoints
included 52.9% (92/174) of laboratories reporting ceftri-
axone and 52.0% (104/200) of laboratories reporting
cefotaxime. One hundred and twelve of 262 laboratories
tested both ceftriaxone and cefotaxime, 88 laboratories
tested only cefotaxime, and 62 laboratories tested only
ceftriaxone in April-June 2003.
Ceftriaxone (n = 7,940) and cefotaxime (n = 4,887) MICs
for nonmeningeal S. pneumoniae isolates were interpreted
by applying both the M100-S11 and the M100-S12 inter-
pretive criteria (Table 2). The proportion of isolates inter-
preted as susceptible increased by 9.9% for ceftriaxone
and 13.5% for cefotaxime when interpreted using M100-
S12 nonmeningeal breakpoints. The proportion of iso-
lates interpreted as intermediate decreased by 7.6% and
10.9% and the proportion of isolates interpreted as resist-
ant decreased by 2.2% and 2.6% for ceftriaxone and cefo-
taxime, respectively, when interpreted using M100-S12
nonmeningeal breakpoints.
Table 1: Implementation of NCCLS M100-S12 MIC breakpoints for expanded-spectrum cephalosporins tested against nonmeningeal 
isolates of S. pneumoniae by US clinical laboratories from January 2002 to June 2003
Number of laboratories (%) using the following 
breakpoints:
Antimicrobial agent(s) Quarter of 2002 and 2003 Total No. of laboratories 
with assessable data
M100-S11 M100-S12
no. (%) no. (%)
Ceftriaxone and/or cefotaxime January-March 2002 216 168 (77.8) 48 (22.2)
April-June 2002 231 157 (68.0) 74 (32.0)
July-September 2002 250 160 (64.0) 90 (36.0)
October-December 2002 256 147 (57.4) 109 (42.6)
January-March 2003 260 135 (51.9) 125 (48.1)
April-June 2003 262 85 (32.4) 177 (67.6)
Ceftriaxone January-March 2002 119 93 (78.2) 26 (21.8)
April-June 2002 135 82 (60.7) 53 (39.3)
July-September 2002 163 94 (57.7) 69 (42.3)
October-December 2002 166 92 (55.4) 74 (44.6)
January-March 2003 172 78 (45.3) 94 (54.7)
April-June 2003 174 82 (47.1) 92 (52.9)
Cefotaxime January-March 2002 158 142 (89.9) 16 (10.1)
April-June 2002 168 143 (85.1) 25 (14.9)
July-September 2002 186 159 (85.5) 27 (14.5)
October-December 2002 196 141 (71.9) 55 (28.1)
January-March 2003 200 137 (68.5) 63 (31.5)
April-June 2003 200 96 (48.0) 104 (52.0)
Table 2: Susceptibility of nonmeningeal isolates of S. pneumoniae recovered from January 2002 to June 2003 to expanded-spectrum 
cephalosporins using both M100-S11 and M100-S12 NCCLS standards
Antimicrobial agent Total no. of isolates NCCLS standard % Susceptible % Intermediate % Resistant
Ceftriaxone 7,940 M100-S11 86.9 9.9 3.2
M100-S12 96.8 2.3 1.0
Cefotaxime 4,887 M100-S11 82.4 13.5 4.1
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Conclusions
Based on MIC and MIC interpretation data submitted by
participating TSN laboratories, we conclude that 67.6% of
all laboratories with interpretable data for S. pneumoniae
tested against expanded-spectrum cephalosporins had
implemented the M100-S12 breakpoints by June 2003.
Approximately one-half (52.9%) of the laboratories with
interpretable data for S. pneumoniae and ceftriaxone and
52.0% of laboratories reporting cefotaxime had imple-
mented the M100-S12 breakpoints by June 2003. The
adoption of the M100-S12 breakpoints is more difficult
for laboratories to implement than previous NCCLS inter-
pretive breakpoints as laboratory information systems
were not designed to accommodate reporting multiple
breakpoints for a single organism-antimicrobial agent
combination. Also, as this is the first instance of multiple
specimen source-specific interpretive breakpoints for a
single organism-antimicrobial agent combination, educa-
tion of laboratory staff and clinicians was required, likely
further complicating the implementation of the new crite-
ria. Continued use of the M100-S11 breakpoints for
expanded-spectrum cephalosporins may lead to the
reporting of false in vitro non-susceptibility of nonmenin-
geal S. pneumoniae isolates. Application of the new inter-
pretative criteria, with higher breakpoints for
nonmeningeal isolates, will result in an increase in the
number of S. pneumoniae isolates reported as susceptible
to cefotaxime and ceftriaxone (Table 2) [2,4]. Based on
analysis of data from January 2002 to June 2003, approx-
imately 10–15% more nonmeningeal isolates will be
reported as susceptible when the M100-S12 breakpoints
are used. The publication and use of the M100-S12 break-
points to interpret meningeal and nonmeningeal isolates
of S. pneumoniae will more accurately reflect the clinical
activities of these agents where the use of an expanded-
spectrum cephalosporin is indicated.
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